" class="no-js "lang="en-US"> Keith Thompson - Medtech Alert
Sunday, September 14, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Keith Thompson

Keith Thompson

About Keith Thompson

Dr. Thompson obtained his Doctorate, Doctor of Medicine, from the University of Western Ontario. He is Fellowship Canadian College Family Practice and Adjunct Faculty Dept Family Medicine UWO, involved in Virtual Care research. He is BCMAS (Board Certified Medical Affairs Specialist) and is working Group Lead for both IEEE SA and WONCA e-Health.

Related Story

Artificial Intelligence

 Researchers Announce AI Models That Can Predict Blood Biomarker Risk | Pharmtech Focus

NuraLogix Researchers Announce AI Models That Can Predict Blood Biomarker Risk

September 1 2022

Researchers at NuraLogix, a global leader in HealthTech AI, announced today that they have developed […]